Levosimendan vs dobutamine for patients with acute decompensated heart failure: The SURVIVE randomized trial

Alexandre Mebazaa, Markku S. Nieminen, Milton Packer, Alain Cohen-Solal, Franz X. Kleber, Stuart J. Pocock, Roopal Thakkar, Robert J. Padley, Pentti Põder, Matti Kivikko

Research output: Contribution to journalArticle

686 Citations (Scopus)

Abstract

Context: Because acute decompensated heart failure causes substantial morbidity and mortality, there is a need for agents that at least improve hemodynamics and relieve symptoms without adversely affecting survival. Objective: To assess the effect of a short-term intravenous infusion of levosimendan or dobutamine on long-term survival. Design, Setting, and Patients: The Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support (SURVIVE) study was a randomized, double-blind trial comparing the efficacy and safety of intravenous levosimendan or dobutamine in 1327 patients hospitalized with acute decompensated heart failure who required inotropic support. The trial was conducted at 75 centers in 9 countries and patients were randomized between March 2003 and December 2004. Interventions: Intravenous levosimendan (n=664) or intravenous dobutamine (n=663). Main Outcome Measure: All-cause mortality at 180 days. Results: All-cause mortality at 180 days occurred in 173 (26%) patients in the levosimendan group and 185 (28%) patients in the dobutamine group (hazard ratio, 0.91; 95% confidence interval, 0.74-1.13; P=.40). The levosimendan group had greater decreases in B-type natriuretic peptide level at 24 hours that persisted through 5 days compared with the dobutamine group (P<.001 for all time points). There were no statistical differences between treatment groups for the other secondary end points (all-cause mortality at 31 days, number of days alive and out of the hospital, patient global assessment, patient assessment of dyspnea at 24 hours, and cardiovascular mortality at 180 days). There was a higher incidence of cardiac failure in the dobutamine group. There were higher incidences of atrial fibrillation, hypokalemia, and headache in the levosimendan group. Conclusion: Despite an initial reduction in plasma B-type natriuretic peptide level in patients in the levosimendan group compared with patients in the dobutamine group, levosimendan did not significantly reduce all-cause mortality at 180 days or affect any secondary clinical outcomes. Trial Registration: clinicaltrials.gov Identifier: NCT00348504.

Original languageEnglish (US)
Pages (from-to)1883-1891
Number of pages9
JournalJournal of the American Medical Association
Volume297
Issue number17
DOIs
StatePublished - May 2 2007

Fingerprint

Dobutamine
Heart Failure
Mortality
Brain Natriuretic Peptide
Survival
simendan
Hypokalemia
Incidence
Intravenous Infusions
Dyspnea
Atrial Fibrillation
Headache
Hemodynamics
Outcome Assessment (Health Care)
Confidence Intervals
Morbidity
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Mebazaa, A., Nieminen, M. S., Packer, M., Cohen-Solal, A., Kleber, F. X., Pocock, S. J., ... Kivikko, M. (2007). Levosimendan vs dobutamine for patients with acute decompensated heart failure: The SURVIVE randomized trial. Journal of the American Medical Association, 297(17), 1883-1891. https://doi.org/10.1001/jama.297.17.1883

Levosimendan vs dobutamine for patients with acute decompensated heart failure : The SURVIVE randomized trial. / Mebazaa, Alexandre; Nieminen, Markku S.; Packer, Milton; Cohen-Solal, Alain; Kleber, Franz X.; Pocock, Stuart J.; Thakkar, Roopal; Padley, Robert J.; Põder, Pentti; Kivikko, Matti.

In: Journal of the American Medical Association, Vol. 297, No. 17, 02.05.2007, p. 1883-1891.

Research output: Contribution to journalArticle

Mebazaa, A, Nieminen, MS, Packer, M, Cohen-Solal, A, Kleber, FX, Pocock, SJ, Thakkar, R, Padley, RJ, Põder, P & Kivikko, M 2007, 'Levosimendan vs dobutamine for patients with acute decompensated heart failure: The SURVIVE randomized trial', Journal of the American Medical Association, vol. 297, no. 17, pp. 1883-1891. https://doi.org/10.1001/jama.297.17.1883
Mebazaa, Alexandre ; Nieminen, Markku S. ; Packer, Milton ; Cohen-Solal, Alain ; Kleber, Franz X. ; Pocock, Stuart J. ; Thakkar, Roopal ; Padley, Robert J. ; Põder, Pentti ; Kivikko, Matti. / Levosimendan vs dobutamine for patients with acute decompensated heart failure : The SURVIVE randomized trial. In: Journal of the American Medical Association. 2007 ; Vol. 297, No. 17. pp. 1883-1891.
@article{5d190a4c4d334ccf875ff5c27c1ad1d6,
title = "Levosimendan vs dobutamine for patients with acute decompensated heart failure: The SURVIVE randomized trial",
abstract = "Context: Because acute decompensated heart failure causes substantial morbidity and mortality, there is a need for agents that at least improve hemodynamics and relieve symptoms without adversely affecting survival. Objective: To assess the effect of a short-term intravenous infusion of levosimendan or dobutamine on long-term survival. Design, Setting, and Patients: The Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support (SURVIVE) study was a randomized, double-blind trial comparing the efficacy and safety of intravenous levosimendan or dobutamine in 1327 patients hospitalized with acute decompensated heart failure who required inotropic support. The trial was conducted at 75 centers in 9 countries and patients were randomized between March 2003 and December 2004. Interventions: Intravenous levosimendan (n=664) or intravenous dobutamine (n=663). Main Outcome Measure: All-cause mortality at 180 days. Results: All-cause mortality at 180 days occurred in 173 (26{\%}) patients in the levosimendan group and 185 (28{\%}) patients in the dobutamine group (hazard ratio, 0.91; 95{\%} confidence interval, 0.74-1.13; P=.40). The levosimendan group had greater decreases in B-type natriuretic peptide level at 24 hours that persisted through 5 days compared with the dobutamine group (P<.001 for all time points). There were no statistical differences between treatment groups for the other secondary end points (all-cause mortality at 31 days, number of days alive and out of the hospital, patient global assessment, patient assessment of dyspnea at 24 hours, and cardiovascular mortality at 180 days). There was a higher incidence of cardiac failure in the dobutamine group. There were higher incidences of atrial fibrillation, hypokalemia, and headache in the levosimendan group. Conclusion: Despite an initial reduction in plasma B-type natriuretic peptide level in patients in the levosimendan group compared with patients in the dobutamine group, levosimendan did not significantly reduce all-cause mortality at 180 days or affect any secondary clinical outcomes. Trial Registration: clinicaltrials.gov Identifier: NCT00348504.",
author = "Alexandre Mebazaa and Nieminen, {Markku S.} and Milton Packer and Alain Cohen-Solal and Kleber, {Franz X.} and Pocock, {Stuart J.} and Roopal Thakkar and Padley, {Robert J.} and Pentti P{\~o}der and Matti Kivikko",
year = "2007",
month = "5",
day = "2",
doi = "10.1001/jama.297.17.1883",
language = "English (US)",
volume = "297",
pages = "1883--1891",
journal = "JAMA - Journal of the American Medical Association",
issn = "0098-7484",
publisher = "American Medical Association",
number = "17",

}

TY - JOUR

T1 - Levosimendan vs dobutamine for patients with acute decompensated heart failure

T2 - The SURVIVE randomized trial

AU - Mebazaa, Alexandre

AU - Nieminen, Markku S.

AU - Packer, Milton

AU - Cohen-Solal, Alain

AU - Kleber, Franz X.

AU - Pocock, Stuart J.

AU - Thakkar, Roopal

AU - Padley, Robert J.

AU - Põder, Pentti

AU - Kivikko, Matti

PY - 2007/5/2

Y1 - 2007/5/2

N2 - Context: Because acute decompensated heart failure causes substantial morbidity and mortality, there is a need for agents that at least improve hemodynamics and relieve symptoms without adversely affecting survival. Objective: To assess the effect of a short-term intravenous infusion of levosimendan or dobutamine on long-term survival. Design, Setting, and Patients: The Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support (SURVIVE) study was a randomized, double-blind trial comparing the efficacy and safety of intravenous levosimendan or dobutamine in 1327 patients hospitalized with acute decompensated heart failure who required inotropic support. The trial was conducted at 75 centers in 9 countries and patients were randomized between March 2003 and December 2004. Interventions: Intravenous levosimendan (n=664) or intravenous dobutamine (n=663). Main Outcome Measure: All-cause mortality at 180 days. Results: All-cause mortality at 180 days occurred in 173 (26%) patients in the levosimendan group and 185 (28%) patients in the dobutamine group (hazard ratio, 0.91; 95% confidence interval, 0.74-1.13; P=.40). The levosimendan group had greater decreases in B-type natriuretic peptide level at 24 hours that persisted through 5 days compared with the dobutamine group (P<.001 for all time points). There were no statistical differences between treatment groups for the other secondary end points (all-cause mortality at 31 days, number of days alive and out of the hospital, patient global assessment, patient assessment of dyspnea at 24 hours, and cardiovascular mortality at 180 days). There was a higher incidence of cardiac failure in the dobutamine group. There were higher incidences of atrial fibrillation, hypokalemia, and headache in the levosimendan group. Conclusion: Despite an initial reduction in plasma B-type natriuretic peptide level in patients in the levosimendan group compared with patients in the dobutamine group, levosimendan did not significantly reduce all-cause mortality at 180 days or affect any secondary clinical outcomes. Trial Registration: clinicaltrials.gov Identifier: NCT00348504.

AB - Context: Because acute decompensated heart failure causes substantial morbidity and mortality, there is a need for agents that at least improve hemodynamics and relieve symptoms without adversely affecting survival. Objective: To assess the effect of a short-term intravenous infusion of levosimendan or dobutamine on long-term survival. Design, Setting, and Patients: The Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support (SURVIVE) study was a randomized, double-blind trial comparing the efficacy and safety of intravenous levosimendan or dobutamine in 1327 patients hospitalized with acute decompensated heart failure who required inotropic support. The trial was conducted at 75 centers in 9 countries and patients were randomized between March 2003 and December 2004. Interventions: Intravenous levosimendan (n=664) or intravenous dobutamine (n=663). Main Outcome Measure: All-cause mortality at 180 days. Results: All-cause mortality at 180 days occurred in 173 (26%) patients in the levosimendan group and 185 (28%) patients in the dobutamine group (hazard ratio, 0.91; 95% confidence interval, 0.74-1.13; P=.40). The levosimendan group had greater decreases in B-type natriuretic peptide level at 24 hours that persisted through 5 days compared with the dobutamine group (P<.001 for all time points). There were no statistical differences between treatment groups for the other secondary end points (all-cause mortality at 31 days, number of days alive and out of the hospital, patient global assessment, patient assessment of dyspnea at 24 hours, and cardiovascular mortality at 180 days). There was a higher incidence of cardiac failure in the dobutamine group. There were higher incidences of atrial fibrillation, hypokalemia, and headache in the levosimendan group. Conclusion: Despite an initial reduction in plasma B-type natriuretic peptide level in patients in the levosimendan group compared with patients in the dobutamine group, levosimendan did not significantly reduce all-cause mortality at 180 days or affect any secondary clinical outcomes. Trial Registration: clinicaltrials.gov Identifier: NCT00348504.

UR - http://www.scopus.com/inward/record.url?scp=34247857479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247857479&partnerID=8YFLogxK

U2 - 10.1001/jama.297.17.1883

DO - 10.1001/jama.297.17.1883

M3 - Article

C2 - 17473298

AN - SCOPUS:34247857479

VL - 297

SP - 1883

EP - 1891

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0098-7484

IS - 17

ER -